WINT - Windtree Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
7.92
+0.32 (+4.21%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close7.60
Open7.49
Bid0.00 x 800
Ask0.00 x 1000
Day's Range7.12 - 8.26
52 Week Range1.50 - 10.50
Volume79,163
Avg. Volume8,625
Market Cap108.482M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateApr 02, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.30
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Windtree Therapeutics Announces Closing of $23 Million Public Offering Including Full Exercise of Over-Allotment Option
    PR Newswire

    Windtree Therapeutics Announces Closing of $23 Million Public Offering Including Full Exercise of Over-Allotment Option

    Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, today announced the closing of its previously announced public offering of 2,758,620 units at a price to the public of $7.25 per unit and the exercise in full of the underwriters' option to purchase 413,793 additional shares of common stock and 413,793 additional warrants. Each unit issued in the offering consisted of one share of common stock and one warrant to purchase one share of common stock at an exercise price of $7.975 per share. The warrants are exercisable for five years from the date of issuance. The common stock and warrants were immediately separable from the units and were issued separately.

  • Windtree Therapeutics Announces Pricing of $20.0 Million Public Offering and Uplisting to the Nasdaq Capital Market
    PR Newswire

    Windtree Therapeutics Announces Pricing of $20.0 Million Public Offering and Uplisting to the Nasdaq Capital Market

    Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, today announced the pricing of its public offering of 2,758,620 units at a price to the public of $7.25 per unit. Each unit issued in the offering consists of one share of common stock and one warrant to purchase one share of common stock at an exercise price of $7.975 per share. The warrants are exercisable for five years from the date of issuance. The common stock and warrants will be immediately separable from the units and will be issued separately. Windtree expects to receive gross proceeds of $20 million, before deducting underwriting discounts and commissions and other estimated offering expenses.

  • Windtree Therapeutics Reports First Quarter 2020 Financial Results and Provides Key Business Updates
    PR Newswire

    Windtree Therapeutics Reports First Quarter 2020 Financial Results and Provides Key Business Updates

    Windtree Therapeutics, Inc. (OTCQB: WINTD), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, today reported financial results for the first quarter ended March 31, 2020 and provided key business updates.

  • Windtree Announces First Patient Enrolled in AEROSURF® Bridging Study for the Treatment of Respiratory Distress Syndrome
    PR Newswire

    Windtree Announces First Patient Enrolled in AEROSURF® Bridging Study for the Treatment of Respiratory Distress Syndrome

    Windtree Therapeutics, Inc. (OTCQB: WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, today announced it has enrolled the first patient into its AEROSURF® phase 2b bridging study in premature infants with respiratory distress syndrome (RDS). This bridging study is intended to complete the phase 2 clinical program for AEROSURF and transition clinical development to phase 3 by validating the performance of the new aerosol delivery system (ADS) in the neonatal intensive care unit (NICU) and a more intensive dosing regimen.

  • Windtree Therapeutics Announces Reverse Stock Split
    PR Newswire

    Windtree Therapeutics Announces Reverse Stock Split

    Windtree Therapeutics, Inc. (OTCQB: WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, today announced a 1-for-3 reverse stock split of its issued and outstanding common stock. The Company's common stock will begin trading on a split-adjusted basis at the opening of the OTCQB® Market on Wednesday, April 29, 2020 under the symbol "WINTD". After 20 trading days, the symbol will revert to WINT. Effective with the reverse split, a new CUSIP number of 97382D 303 has been assigned to the Company's common stock. The number of shares of common stock authorized under the Company's Amended and Restated Certificate of Incorporation is unchanged at 120 million shares.

  • Windtree Presents New Istaroxime Phase 2b Study Analysis at the American College of Cardiology (ACC) Congress
    PR Newswire

    Windtree Presents New Istaroxime Phase 2b Study Analysis at the American College of Cardiology (ACC) Congress

    Windtree Therapeutics, Inc. (OTCQB: WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, today announced the presentation of a new subset analysis from a phase 2b study of istaroxime in patients hospitalized with acute heart failure (AHF) at the American College of Cardiology (ACC) 2020 virtual meeting. The company previously presented the overall results of the study where the primary endpoint demonstrated a significant improvement (p<0.05) in cardiac function at both istaroxime study doses. This post-hoc analysis characterized the responses between Caucasian and Asian patients. The istaroxime dose of 0.5 µg/kg/min produced a similar response on E/e', the primary study endpoint, and stroke volume index, an important measure of cardiac performance, in Asian and Caucasian patients.

  • Windtree Therapeutics Reports Fourth Quarter 2019 Financial Results and Provides Key Business Updates
    PR Newswire

    Windtree Therapeutics Reports Fourth Quarter 2019 Financial Results and Provides Key Business Updates

    Windtree Therapeutics, Inc. (OTCQB: WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, today reported financial results for the fourth quarter ended December 31, 2019 and provided key business updates.

  • Windtree Enters into Agreement with Lee's Pharmaceutical for Non-Dilutive Funding of the Continued Development of AEROSURF®
    PR Newswire

    Windtree Enters into Agreement with Lee's Pharmaceutical for Non-Dilutive Funding of the Continued Development of AEROSURF®

    Windtree Therapeutics, Inc. (OTCQB: WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, announces it has entered into a binding term sheet (the "Term Sheet") with Lee's Pharmaceutical Holdings (HK) Ltd ("Lee's") pursuant to which Lee's will provide project financing for the continued development of the Company's lead acute pulmonary product candidate, AEROSURF® for the treatment of preterm infants with respiratory distress syndrome ("RDS"). The financing will fund the AEROSURF phase 2b bridge study which, if successful, is intended to transition the product into a phase 3 ready clinical product development.

  • Windtree to Pursue Clinical Study of Lung Injury Treatment in COVID-19 Patients with its KL4 Surfactant Therapy
    PR Newswire

    Windtree to Pursue Clinical Study of Lung Injury Treatment in COVID-19 Patients with its KL4 Surfactant Therapy

    Windtree Therapeutics, Inc. (OTCQB: WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, today announced it is planning to study its proprietary KL4 surfactant to potentially mitigate the pulmonary effects of severe COVID-19 infection. The Company is actively pursuing several non-dilutive opportunities to fund this project, including government agencies and private foundations.

  • Windtree to Host a Conference Call on December 11, 2019 to Provide Development Programs and Financial Update
    PR Newswire

    Windtree to Host a Conference Call on December 11, 2019 to Provide Development Programs and Financial Update

    Windtree Therapeutics, Inc. (OTCQB: WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, will host a conference call and webcast (including a slide presentation) at 8:00 AM EST on Wednesday, December 11, 2019 to provide updates on its acute cardiovascular and pulmonary clinical programs, the recently announced $26.4 million private offering and other business initiatives.

  • Windtree Therapeutics Completes $26.4 Million Private Placement
    PR Newswire

    Windtree Therapeutics Completes $26.4 Million Private Placement

    Windtree Therapeutics, Inc. (OTCQB: WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, today announced that it has completed a $26.4 million private placement of common stock and warrants. In connection with this offering, the Company issued 8,749,999 shares of common stock at a purchase price of $3.02 per share and warrants to purchase 4,375,002 shares of common stock at an exercise price of $4.03 per share.

  • Windtree Therapeutics Provides Business Update
    PR Newswire

    Windtree Therapeutics Provides Business Update

    WARRINGTON, Pa., Oct. 25, 2019 /PRNewswire/ -- Windtree Therapeutics, Inc. (WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, today provided updates on its lead development programs and business operations. "During the third quarter, we made substantive progress in two of our lead development programs – istaroxime for acute heart failure (AHF) and early cardiogenic shock, and AEROSURF® for respiratory distress syndrome (RDS) in premature infants.

  • GlobeNewswire

    Windtree Therapeutics to Present at the Fall Investor Summit

    WARRINGTON, Pa., Sept. 10, 2019 -- Windtree Therapeutics, Inc. (OTCQB: WINT), a biotechnology and medical device company focused on developing drug product candidates and.

  • Windtree Therapeutics Announces Publication of Results of Lung Deposition Study of Aerosolized Lucinactant
    PR Newswire

    Windtree Therapeutics Announces Publication of Results of Lung Deposition Study of Aerosolized Lucinactant

    WARRINGTON, Pa., Sept. 6, 2019 /PRNewswire/ -- Windtree Therapeutics, Inc. (WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, today announced the full publication of previously described results of a lung deposition study conducted in non-human primates (NHPs) that demonstrated the Company's proprietary aerosol delivery system (ADS) is capable of delivering aerosolized lucinactant (the Company's lyophilized KL4 surfactant) throughout all regions of the lung. The study was performed in collaboration with Lovelace Biomedical and is published in the Journal of Aerosol Medicine and Pulmonary Drug Delivery. The study consisted of a series of experiments in NHPs designed to assess the distribution and deposition of aerosolized lucinactant in the lung when administered using the ADS. The Company has developed the ADS as part of its AEROSURF® (lucinactant for inhalation) development program.

  • PR Newswire

    Windtree Therapeutics Reports Second Quarter 2019 Financial Results and Provides Key Business Updates

    WARRINGTON, Pa. , Aug. 14, 2019 /PRNewswire/ --   Windtree Therapeutics, Inc. (OTCQB: WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device ...

  • PR Newswire

    Windtree Announces FDA Fast Track Designation for Istaroxime

    WARRINGTON, Pa., Aug. 13, 2019 /PRNewswire/ -- Windtree Therapeutics, Inc. (WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for istaroxime for the treatment of acute heart failure.

  • Windtree Therapeutics to Host Research & Development Day in New York City on June 25
    PR Newswire

    Windtree Therapeutics to Host Research & Development Day in New York City on June 25

    WARRINGTON, Pa., June 19, 2019 /PRNewswire/ -- Windtree Therapeutics, Inc. (WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, announced today that it will host a research and development (R&D) day in New York City on Tuesday, June 25 from 8:00 am – 9:30 am EDT. The R&D Day will feature presentations of Windtree's two lead therapeutic areas of acute heart failure and respiratory distress syndrome in premature infants delivered by key thought leaders in these respective fields.  Marco Metra, MD, from the University and Civil Hospitals of Brescia, Italy, will discuss the current treatment landscape and unmet medical need in treating patients with heart failure, and Fernando Moya, MD, from the Coastal Children's Services and New Hanover Regional Medical Center, will discuss the unmet medical need in treating premature infants with respiratory distress syndrome.

  • Windtree and Eleison Announce Initial Results of Delivering Inhaled Lipid Cisplatin (ILC) Utilizing Windtree's Drug Delivery Technology
    PR Newswire

    Windtree and Eleison Announce Initial Results of Delivering Inhaled Lipid Cisplatin (ILC) Utilizing Windtree's Drug Delivery Technology

    WARRINGTON, Pa. and PRINCETON, N.J., June 4, 2019 /PRNewswire/ -- Windtree Therapeutics, Inc. (WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, and Eleison Pharmaceuticals LLC, a specialty pharmaceutical company developing life-saving therapeutics for rare cancers, today jointly announced positive results of the feasibility study using Windtree's proprietary Aerosol Delivery System (ADS) aerosolization technology to deliver Eleison's inhaled lipid cisplatin (ILC).

  • Istaroxime Phase 2b Study Results Presented in Late Breaker Clinical Trial Session at the ESC Heart Failure Congress
    PR Newswire

    Istaroxime Phase 2b Study Results Presented in Late Breaker Clinical Trial Session at the ESC Heart Failure Congress

    WARRINGTON, Pa., May 30, 2019 /PRNewswire/ -- Windtree Therapeutics, Inc. (WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, today announced the presentation of new safety and efficacy data from a phase 2b study of istaroxime in patients hospitalized with acute heart failure (AHF) at a late-breaker session of the European Society of Cardiology (ESC) 2019 Heart Failure Congress. The study achieved its primary endpoint by demonstrating a significant improvement (p<0.05) in cardiac function at both istaroxime study doses.